Rekor Systems Prices 8,571,428 Units Direct Offering at $1.75 Each
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Rekor Systems announced the pricing of an underwritten registered direct offering of 8,571,428 units at a public offering price of $1.75 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.40 per share. The warrants will be immediately exercisable and will expire seven years from the date of issuance. The shares of common stock and warrants comprising the units are immediately separable and will be issued separately. The offering is expected to close on or about December 16, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds to Rekor from the offering are expected to be approximately $15M, before deducting underwriting discounts and commissions and other offering expenses payable by Rekor. Rekor intends to use the net proceeds from this offering for working capital, capital expenditures and general corporate purposes. The offering included participation from one institutional investor. William Blair is acting as the sole book-running manager for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RKDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RKDA
About RKDA
Arcadia Biosciences, Inc. is a producer and marketer of plant-based health and wellness products. The Company’s product portfolio includes Zola Coconut Water (Zola) and Agronomic Wheat Traits. Zola is a natural, 100% coconut water. Zola is a non-genetically modified organisms (non-GMO) project verified and only contains 60 calories per serving. Zola flavors include original, original with pulp, espresso, lime and pineapple. The recipe with Zola includes smoothies, desserts, cocktails and mocktails, and bowls. It has developed a portfolio of non-GMO specialty wheat traits to offer healthier, nutrient-rich wheat options while providing the same baking quality, taste, and texture as traditional wheat. Its non-GMO Reduced Gluten High Fiber Wheat has fewer allergenic glutens and higher fiber than traditional wheat, while its non-GMO Extended Shelf-Life Wheat extends the shelf life of milled whole wheat flour.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arcadia Biosciences Closes Private Placement Raising $4 Million
- Financing Size: Arcadia Biosciences has successfully completed a private placement of 3,883,496 shares of common stock, raising approximately $4 million, indicating the company's active engagement in capital markets and its financing capabilities.
- Investment Options Details: The financing includes Series A-1 and A-2 preferred investment options, both priced at an exercise price of $0.91 per share, with A-1 options exercisable upon shareholder approval and A-2 options immediately exercisable, enhancing investor flexibility.
- Use of Proceeds: The company intends to utilize the proceeds for working capital and general corporate purposes, which will support the development and marketing of its innovative products, further solidifying its competitive position in the wellness product sector.
- Compliance Statement: The securities offered were conducted under Section 4(a)(2) of the Securities Act of 1933, remaining unregistered in the U.S., reflecting the company's cautious approach to compliance and ensuring future capital operations adhere to relevant laws and regulations.
See More
Arcadia Biosciences Announces Private Placement of Common Stock
- Private Placement Agreement: Arcadia Biosciences (RKDA) has entered into securities purchase agreements for a private placement of approximately 3.88 million shares of common stock at a price of $1.03 per share, aiming to raise about $4 million in gross proceeds, indicating the company's ability to access capital markets.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated for working capital and general corporate purposes, highlighting the company's focus on liquidity in the current market environment, which is intended to enhance its operational capacity and competitive position.
- Transaction Timeline: The offering is expected to close on or about June 12, demonstrating the company's efficiency in responding to market demands and capital raising, which will help maintain flexibility in future business development.
- Stock Price Impact: Following the announcement of the financing, RKDA's stock traded about 8% lower during pre-market hours on Friday, reflecting market caution regarding the financing plan and potentially affecting investor confidence in the company's future performance.
See More
Arcadia Biosciences Announces Stock Offering
- Stock Offering Announcement: Arcadia Biosciences has entered into agreements to sell 3.88 million shares of common stock and Series A-1 and A-2 preferred investment options, with expected gross proceeds of approximately $4 million, indicating a proactive approach to financing.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized for working capital and general corporate purposes, reflecting the company's strategic intent to expand operations and enhance financial flexibility.
- Negative Market Reaction: Despite the offering price set at $1.03 per share, RKDA's stock fell by 3.74% in the latest trading session and further declined by 5.61% in after-hours trading, signaling investor concerns regarding the company's outlook.
- Investor Attention on Expiration: The Series A-1 options expire five years after shareholder approval, while the Series A-2 options expire 24 months after the effectiveness of the resale registration statement, necessitating investor awareness of these timelines and their implications for future financing.
See More
Arcadia Biosciences Announces Private Placement of Common Stock
- Financing Size: Arcadia Biosciences announced a private placement of 3,883,496 shares of common stock, with expected gross proceeds of approximately $4 million, which will be utilized for working capital and general corporate purposes, thereby enhancing the company's financial flexibility.
- Preferred Investment Options: The offering includes Series A-1 and A-2 preferred investment options, both priced at an exercise price of $0.91 per share, with A-1 options exercisable upon shareholder approval and A-2 options immediately, indicating the company's proactive approach to future capital operations.
- Market Compliance: The securities are offered under Section 4(a)(2) of the Securities Act of 1933, remaining unregistered in the U.S., reflecting the company's cautious stance on compliance while also limiting the liquidity of the securities, which may affect investor participation.
- Future Outlook: The company plans to close the offering on June 12, 2026, subject to customary closing conditions, and if successful, this will provide essential funding support for its future operations and innovations, aiding its further development in the health products market.
See More
Arcadia Biosciences Reports Q4 Financial Results
- Disappointing Financial Results: Arcadia Biosciences reported a Q4 GAAP EPS of -$0.97, indicating significant challenges in profitability and reflecting ongoing financial pressures on the company.
- Significant Revenue Decline: The company’s Q4 revenue was $0.9 million, down 26.2% year-over-year, a trend that may undermine investor confidence in the company’s future growth potential, particularly in the competitive biotech sector.
- Negative Market Reaction: The earnings report, which fell short of market expectations, could lead investors to adopt a cautious stance regarding the company’s future financial performance, potentially putting pressure on the stock price and affecting its ability to raise capital and pursue strategic investments.
- Need for Strategic Reevaluation: In light of the ongoing revenue decline, Arcadia Biosciences may need to reassess its business model and market strategies to achieve sustainable growth in the future and restore investor confidence.
See More
Arcadia Biosciences Reports Q4 Operating Expenses of $2.276 Million
Operating Expenses: The operating expenses for Arcadia Biosciences in the fourth quarter amounted to USD 2.276 million.
Financial Overview: The report highlights the financial performance and expenditures of the company during the specified quarter.
Company Focus: Arcadia Biosciences is engaged in biotechnology, focusing on developing innovative agricultural solutions.
Future Outlook: The financial results may influence future investments and strategic decisions for the company moving forward.
See More
Arcadia Biosciences Closes Private Placement Raising $4 Million
- Financing Size: Arcadia Biosciences has successfully completed a private placement of 3,883,496 shares of common stock, raising approximately $4 million, indicating the company's active engagement in capital markets and its financing capabilities.
- Investment Options Details: The financing includes Series A-1 and A-2 preferred investment options, both priced at an exercise price of $0.91 per share, with A-1 options exercisable upon shareholder approval and A-2 options immediately exercisable, enhancing investor flexibility.
- Use of Proceeds: The company intends to utilize the proceeds for working capital and general corporate purposes, which will support the development and marketing of its innovative products, further solidifying its competitive position in the wellness product sector.
- Compliance Statement: The securities offered were conducted under Section 4(a)(2) of the Securities Act of 1933, remaining unregistered in the U.S., reflecting the company's cautious approach to compliance and ensuring future capital operations adhere to relevant laws and regulations.
See More
Arcadia Biosciences Announces Private Placement of Common Stock
- Private Placement Agreement: Arcadia Biosciences (RKDA) has entered into securities purchase agreements for a private placement of approximately 3.88 million shares of common stock at a price of $1.03 per share, aiming to raise about $4 million in gross proceeds, indicating the company's ability to access capital markets.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated for working capital and general corporate purposes, highlighting the company's focus on liquidity in the current market environment, which is intended to enhance its operational capacity and competitive position.
- Transaction Timeline: The offering is expected to close on or about June 12, demonstrating the company's efficiency in responding to market demands and capital raising, which will help maintain flexibility in future business development.
- Stock Price Impact: Following the announcement of the financing, RKDA's stock traded about 8% lower during pre-market hours on Friday, reflecting market caution regarding the financing plan and potentially affecting investor confidence in the company's future performance.
See More
Arcadia Biosciences Announces Stock Offering
- Stock Offering Announcement: Arcadia Biosciences has entered into agreements to sell 3.88 million shares of common stock and Series A-1 and A-2 preferred investment options, with expected gross proceeds of approximately $4 million, indicating a proactive approach to financing.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized for working capital and general corporate purposes, reflecting the company's strategic intent to expand operations and enhance financial flexibility.
- Negative Market Reaction: Despite the offering price set at $1.03 per share, RKDA's stock fell by 3.74% in the latest trading session and further declined by 5.61% in after-hours trading, signaling investor concerns regarding the company's outlook.
- Investor Attention on Expiration: The Series A-1 options expire five years after shareholder approval, while the Series A-2 options expire 24 months after the effectiveness of the resale registration statement, necessitating investor awareness of these timelines and their implications for future financing.
See More
Arcadia Biosciences Announces Private Placement of Common Stock
- Financing Size: Arcadia Biosciences announced a private placement of 3,883,496 shares of common stock, with expected gross proceeds of approximately $4 million, which will be utilized for working capital and general corporate purposes, thereby enhancing the company's financial flexibility.
- Preferred Investment Options: The offering includes Series A-1 and A-2 preferred investment options, both priced at an exercise price of $0.91 per share, with A-1 options exercisable upon shareholder approval and A-2 options immediately, indicating the company's proactive approach to future capital operations.
- Market Compliance: The securities are offered under Section 4(a)(2) of the Securities Act of 1933, remaining unregistered in the U.S., reflecting the company's cautious stance on compliance while also limiting the liquidity of the securities, which may affect investor participation.
- Future Outlook: The company plans to close the offering on June 12, 2026, subject to customary closing conditions, and if successful, this will provide essential funding support for its future operations and innovations, aiding its further development in the health products market.
See More
Arcadia Biosciences Reports Q4 Financial Results
- Disappointing Financial Results: Arcadia Biosciences reported a Q4 GAAP EPS of -$0.97, indicating significant challenges in profitability and reflecting ongoing financial pressures on the company.
- Significant Revenue Decline: The company’s Q4 revenue was $0.9 million, down 26.2% year-over-year, a trend that may undermine investor confidence in the company’s future growth potential, particularly in the competitive biotech sector.
- Negative Market Reaction: The earnings report, which fell short of market expectations, could lead investors to adopt a cautious stance regarding the company’s future financial performance, potentially putting pressure on the stock price and affecting its ability to raise capital and pursue strategic investments.
- Need for Strategic Reevaluation: In light of the ongoing revenue decline, Arcadia Biosciences may need to reassess its business model and market strategies to achieve sustainable growth in the future and restore investor confidence.
See More
Arcadia Biosciences Reports Q4 Operating Expenses of $2.276 Million
Operating Expenses: The operating expenses for Arcadia Biosciences in the fourth quarter amounted to USD 2.276 million.
Financial Overview: The report highlights the financial performance and expenditures of the company during the specified quarter.
Company Focus: Arcadia Biosciences is engaged in biotechnology, focusing on developing innovative agricultural solutions.
Future Outlook: The financial results may influence future investments and strategic decisions for the company moving forward.
See More
